Differential diagnosis of serous ovarian tumors using mass spectrometry-based serum lipid profiling: a pilot study


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Background: Due to lacking effective methods for early diagnosis, ovarian cancer (OC) is the leading cause of death from gynecologic malignancies. Aim: To make a differential diagnosis of ovarian serous malignant and borderline tumors and investigate changes in serum lipidome after treatment using high-performance liquid chromatography with mass spectrometry (HPLC-MS). Materials and methods: The study included 53 patients with high-grade serous ovarian carcinoma (HGSOC) and serous borderline tumors (SBT) who underwent surgery at the V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia and 10 patients in control groups. Lipids were extracted from the serum using a modified Folch method and analyzed by HPLC-MS. Statistical analysis was performed by the OPLS multivariate analysis. The statistical significance of between-group differences was tested with a nonparametric Mann-Whitney test with Benjamini-Hochberg correction. Results: Based on statistically significant differences in serum lipid profiles (phosphatidylcholines, glycerolipids, etc.), differential diagnostic models were developed clustering patients with early and advanced stages of HGSOC, SBT, and control groups (model parameters: R2≥0.5, Q2≥0.4). No systemic changes in the lipidome were found after non-radical surgery. Changes in the lipid profiles were observed after NACT. An increase in serum lysophosphatidylcholine derivatives [OxLPC(22:2(OO))] and glycerophospholipids [PEtOH(20:1_20:1)-H] was proportional to the likelihood of HGSOC recurrence or progression within a year after combined treatment. Conclusion: The study findings suggest that mass spectrometry-based serum lipid profiling can improve serous ovarian tumors' identification and differential diagnosis in various clinical situations.

Texto integral

Acesso é fechado

Sobre autores

Mania Iurova

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University Ministry of Health of Russia (Sechenov University)

Email: m_yurova@oparina4.ru
Specialist, V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia; PhD. Student at the Chair; the Faculty of Postgraduate Professional Training of Physicians 117997, Russia, Moscow, Ac. Oparina, 4

Vitaliy Chagovets

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology Ministry of Health of Russia

Email: vvchagovets@gmail.com
PhD., Senior Researcher at the Laboratory of Proteomics and Metabolomics in Human Reproduction, Department of Systems Biology 117997, Russia, Moscow, Ac. Oparina, 4

Vladimir Frankevich

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology Ministry of Health of Russia

Email: v_frankevich@oparina4.ru
Ph.D., Head of Department of Systems Biology in Reproduction 117997, Russia, Moscow, Ac. Oparina, 4

Nataliia Starodubtseva

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology Ministry of Health of Russia

Email: n_starodubtseva@oparina4ru
Ph.D., Head of Laboratory of Proteomics and Metabolomics of Human Reproduction 117997, Russia, Moscow, Ac. Oparina, 4

Grigory Khabas

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology Ministry of Health of Russia

Email: g_khabas@oparina4.ru
Ph.D., surgeon, oncologist, obstetrician-gynecologist, Head of the Department of Innovative Oncology and Gynecology 117997, Russia, Moscow, Ac. Oparina, 4

Stanislav Pavlovich

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University Ministry of Health of Russia (Sechenov University)

Email: s_pavlovich@oparina4ru
PhD., Academic Secretary, V.I. Kulakov NMRC for OG&P; Professor at the Department of Obstetrics, Gynecology, Perinatology and Reproductology, Faculty of Postgraduate Professional Training of Physicians 117997, Russia, Moscow, Ac. Oparina, 4

Bibliografia

  1. Gaul D.A., Mezencev R., Long T.Q., Jones C.M., Benigno B.B., Gray A. et al. Highly-accurate metabolomic detection of early-stage ovarian cancer. Sci. Rep. 2015; 5: 16351. https://dx.doi.org/10.1038/srep16351.
  2. Amoroso M.R., Matassa D.S., Agliarulo I., Avolio R., Maddalena F., Condelli V. et al. Stress-adaptive response in ovarian cancer drug resistance: Role of TRAP1 in oxidative metabolism-driven inflammation. Adv. Protein Chem. Struct. Biol. 2017; 108: 163-98. https://dx.doi.org/10.1016/bs.apcsb.2017.01.004.
  3. Каприн А.Д., Старинский В.В., Шахзадова А.О., ред. Состояние онкологической помощи населению России в 2019 году. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2020. 239с.
  4. Ueland F.R., Li A.J. Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum. URL: http://www.uptodate.com/contents/serum-biomarkers-for-evaluation-of-an-adnexal-mass-for-epithelial-carcinoma-of-the-ovary-fallopian-tube-or-peritoneum.
  5. Tomao F., Di Pinto A., Sassu C.M., Bardhi E., Di Donato V., Muzii L. et al. Fertility preservation in ovarian tumours. Ecancermedicalscience. 2018; 12: 885. https://dx.doi.org/10.3332/ecancer.2018.885.
  6. Ashraf M.A., Dasari P. Outcome of fertility-preserving surgery for ovarian malignancy in young women. Case Rep. 2018; 1(1): 51-4.
  7. Bekelman D.B., Hooker S., Nowels C. T., Main D.S., Meek P., McBryde C. et al. Feasibility and acceptability of a collaborative care intervention to improve symptoms and quality of life in chronic heart failure: mixed methods pilot trial. J. Palliat. Med. 2014; 17(2): 145-51.
  8. Warren L.A., Shih A., Renteira S.M., Seckin T., Blau B., Simpfendorfer K. et al. Analysis of menstrual effluent: Diagnostic potential for endometriosis. Mol. Med. 2018; 24(1): 1-12.
  9. Ghahremanfard F., Mirmohammadkhani M., Shahnazari B., Gholami G., Mehdizadeh J. The valuable role of measuring serum lipid profile in cancer progression. Oman Med. J. 2015; 30(5): 353-7 https://dx.doi.org/10.5001/omj.2015.71.
  10. Havrilesky L., Darcy K.M., Hamdan H., Priore R.L., Leon J., Bell J. et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study. J. Clin. Oncol. 2003; 21(20): 3814-25. https://dx.doi.org/10.1200/JCO.2003.11.052.
  11. Cha Y.J., Koo J.S. Roles of omental and bone marrow adipocytes in tumor biology. Adipocyte. 2019; 8(1): 304-17.
  12. Hu J., Liu Z., Wang X. Does TP53 mutation promote ovarian cancer metastasis to omentum by regulating lipid metabolism? Med. Hypotheses. 2013; 81(4): 515-20. https://dx.doi.org/10.1016/j.mehy.2013.06.009.
  13. Jelonek K., Ros M., Pietrowska M., Widlak P. Cancer biomarkers and mass spectrometry-based analyses of phospholipids in body fluids. Clin. Lipidol. 2013; 8(1): 137-50. https://dx.doi.org/10.2217/clp.12.79.
  14. Li J., Xie H., Li A., Cheng J., Yang K., Wang J. et al. Distinct plasma lipids profiles of recurrent ovarian cancer by liquid chromatography-mass spectrometry. Oncotarget. 2017; 8(29): 46834-45. https://dx.doi.org/10.18632/oncotarget.11603.
  15. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957; 226(1): 497-509.
  16. Chambers M.C., Maclean B., Burke R., Amodei D., Ruderman D.L., Neumann S. et al. A cross-platform toolkit for mass spectrometry and proteomics. Nat. Biotechnol. 2012; 30(10): 918-20. https://dx.doi.org/10.1038/nbt.2377.
  17. Pluskal T., Castillo S., Villar-Briones A., Oresic M. MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics. 2010; 11: 395. https://dx.doi.org/10.1186/1471-2105-11-395.
  18. Koelmel J.P., Kroeger N.M., Ulmer C.Z., Bowden J.A., Patterson R.E., Cochran J.A. et al. LipidMatch: An automated workflow for rule-based lipid identification using untargeted high-resolution tandem mass spectrometry data. BMC Bioinformatics. 2017; 18(1): 331. https://dx.doi.org/10.1186/s12859-017-1744-3.
  19. Sud M., Fahy E., Cotter D., Brown A., Dennis E.A., Glass C.K. et al. LMSD: LIPID MAPS structure database. Nucleic Acids Res. 2007; 35(Database issue): D527-32. https://dx.doi.org/10.1093/nar/gkl838.
  20. R : A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2018.
  21. R team. R Studio: Integrated Development for R. Boston, MA: RStudio, Inc.; 2016.
  22. Trygg J, Wold S. Orthogonal projections to latent structures (O-PLS). J. Chemom. 2002; 16(3): 119-28.
  23. Thevenot E.A., Roux A., Xu Y., Ezan E., Junot C. Analysis of the human adult urinary metabolome variations with age, body mass index, and gender by implementing a comprehensive workflow for univariate and OPLS statistical analyses. J. Proteome Res. 2015; 14(8): 3322-35. https://dx.doi.org/10.1021/acs.jproteome.5b00354.
  24. Wold S., Sjostrom M., Eriksson L. PLS-regression: a basic tool of chemometrics. Chemom. Intell. Lab. Syst. 2001; 58(2): 109-30.
  25. Buas M.F., Gu H, Djukovic D., Zhu J., Drescher C.W., Urban N. et al. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors. Gynecol. Oncol. 2016; 140(1): 138-44. https://dx.doi.org/10.1016/j.ygyno.2015.10.021.
  26. Niemi R.J., Braicu E.I., Kulbe H, Koistinen K.M., Sehouli J., Puistola U. et al. Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism. Br. J. Cancer. 2018; 119(7): 847-54. https://dx.doi.org/10.1038/s41416-018-0270-z.
  27. Knapp P., Bodnar L., Blachnio-Zabielska A., Swiderska M., Chabowski A. Plasma and ovarian tissue sphingolipids profiling in patients with advanced ovarian cancer. Gynecol. Oncol. 2017; 147(1): 139-44. https://dx.doi.org/10.1016/j.ygyno.2017.07.143.
  28. Kedem A., Yerushalmi G.M., Brengauz M., Raanani H., Orvieto R., Hourvitz A., Meirow D. Outcome of immature oocytes collection of 119 cancer patients during ovarian tissue harvesting for fertility preservation. J. Assist. Reprod. Genet. 2018; 35(5): 851-6. https://dx.doi.org/10.1007/s10815-018-1153-1.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2021

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies